Matches in SemOpenAlex for { <https://semopenalex.org/work/W3003550806> ?p ?o ?g. }
- W3003550806 endingPage "100536" @default.
- W3003550806 startingPage "100536" @default.
- W3003550806 abstract "The main objective of the French GETUG/AFU V05 VESPER randomized phase III study was to assess the efficacy of dd-MVAC and GC in term of progression-free survival in patients for whom chemotherapy has been decided, before or after surgery. A total of 500 patients have been randomized in 28 reference centers. Inclusion criteria were urothelial carcinoma without neuro-endocrine variant, disease defined by a T2, T3 or T4a N0 (pelvic lymph node ≤ 10 mm on CT scan) M0 staging for patients receiving neoadjuvant chemotherapy or pT3 or pT4 or pN+ and M0 for patients receiving adjuvant chemotherapy. Secondary endpoints include overall survival, safety, response rate. The peri-operative chemotherapy schedule was experimental arm dd-MVAC for a total of 6 cycles versus standard arm GC 4 cycles. The toxicity was evaluated according to NCI CTCAE (v 4.0). The progression-free survival rate will be estimated at 3 years by the Kaplan-Meier method. All the patients will be followed for 5 years. The last patient was randomized in March 2018 and the primary endpoint results are expected for mid-2021. As the dd-MVAC schedule is associated with higher response rates in metastatic disease, the real question today is to confirm such benefit in the peri-operative setting, taking also in consideration the chemotherapy toxicity. Tomorrow, the challenge may be the best chemotherapy and immunotherapy association, the authors hope that final Vesper Trial results will help to determine the gold standard chemotherapy." @default.
- W3003550806 created "2020-02-07" @default.
- W3003550806 creator A5001456598 @default.
- W3003550806 creator A5001631575 @default.
- W3003550806 creator A5002709964 @default.
- W3003550806 creator A5006415190 @default.
- W3003550806 creator A5006671522 @default.
- W3003550806 creator A5008104866 @default.
- W3003550806 creator A5010357609 @default.
- W3003550806 creator A5012023155 @default.
- W3003550806 creator A5013005829 @default.
- W3003550806 creator A5013204446 @default.
- W3003550806 creator A5018519159 @default.
- W3003550806 creator A5019361384 @default.
- W3003550806 creator A5020520466 @default.
- W3003550806 creator A5021549650 @default.
- W3003550806 creator A5026949417 @default.
- W3003550806 creator A5027991868 @default.
- W3003550806 creator A5028232952 @default.
- W3003550806 creator A5029703857 @default.
- W3003550806 creator A5030309049 @default.
- W3003550806 creator A5030902321 @default.
- W3003550806 creator A5034429722 @default.
- W3003550806 creator A5035257097 @default.
- W3003550806 creator A5037563163 @default.
- W3003550806 creator A5039428493 @default.
- W3003550806 creator A5040171322 @default.
- W3003550806 creator A5040479101 @default.
- W3003550806 creator A5043484283 @default.
- W3003550806 creator A5043665560 @default.
- W3003550806 creator A5044633214 @default.
- W3003550806 creator A5045928875 @default.
- W3003550806 creator A5046446250 @default.
- W3003550806 creator A5050255590 @default.
- W3003550806 creator A5051297483 @default.
- W3003550806 creator A5057706340 @default.
- W3003550806 creator A5059886680 @default.
- W3003550806 creator A5061630120 @default.
- W3003550806 creator A5061813933 @default.
- W3003550806 creator A5064378838 @default.
- W3003550806 creator A5064914239 @default.
- W3003550806 creator A5065732872 @default.
- W3003550806 creator A5066711887 @default.
- W3003550806 creator A5067675413 @default.
- W3003550806 creator A5068223483 @default.
- W3003550806 creator A5068597606 @default.
- W3003550806 creator A5069754118 @default.
- W3003550806 creator A5074336646 @default.
- W3003550806 creator A5076354847 @default.
- W3003550806 creator A5079244535 @default.
- W3003550806 creator A5081051779 @default.
- W3003550806 creator A5082066678 @default.
- W3003550806 creator A5084444201 @default.
- W3003550806 creator A5085149424 @default.
- W3003550806 creator A5088103291 @default.
- W3003550806 creator A5088337969 @default.
- W3003550806 creator A5088723040 @default.
- W3003550806 creator A5089320369 @default.
- W3003550806 creator A5090538658 @default.
- W3003550806 creator A5090993023 @default.
- W3003550806 date "2020-03-01" @default.
- W3003550806 modified "2023-10-18" @default.
- W3003550806 title "Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial" @default.
- W3003550806 cites W1893588230 @default.
- W3003550806 cites W1964037817 @default.
- W3003550806 cites W1971208896 @default.
- W3003550806 cites W1975918912 @default.
- W3003550806 cites W2033775272 @default.
- W3003550806 cites W2090241022 @default.
- W3003550806 cites W2113156769 @default.
- W3003550806 cites W2147180151 @default.
- W3003550806 cites W2151278059 @default.
- W3003550806 cites W2157244703 @default.
- W3003550806 cites W2160107406 @default.
- W3003550806 cites W2164791945 @default.
- W3003550806 cites W2289712604 @default.
- W3003550806 cites W2308167615 @default.
- W3003550806 cites W2462649057 @default.
- W3003550806 cites W2588916311 @default.
- W3003550806 cites W2604535399 @default.
- W3003550806 cites W2619733974 @default.
- W3003550806 cites W2761432987 @default.
- W3003550806 cites W2773177438 @default.
- W3003550806 cites W2782762180 @default.
- W3003550806 cites W2811458500 @default.
- W3003550806 cites W4299398734 @default.
- W3003550806 doi "https://doi.org/10.1016/j.conctc.2020.100536" @default.
- W3003550806 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7025084" @default.
- W3003550806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32083220" @default.
- W3003550806 hasPublicationYear "2020" @default.
- W3003550806 type Work @default.
- W3003550806 sameAs 3003550806 @default.
- W3003550806 citedByCount "11" @default.
- W3003550806 countsByYear W30035508062020 @default.
- W3003550806 countsByYear W30035508062021 @default.
- W3003550806 countsByYear W30035508062022 @default.
- W3003550806 countsByYear W30035508062023 @default.
- W3003550806 crossrefType "journal-article" @default.